drugset / Trial / NCT06860386
Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase II Clinical Trial that will evaluate the use of adaptive dosing of pembro-axi in patients with Metastatic Clear Cell Renal Cell Carcinoma (mccRCC).
Timeline
- Start
- 2025-02-25
- Primary completion
- 2026-09
- Completion
- 2028-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axitinib | Small molecule | 5 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |